IP Library Granted Patent US 7,074,890
Granted Patent B2
US 7,074,890 · App. 10/926,148 · Granted Jul 11, 2006

Process for preparing glycopeptide phosphonate derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,074,890
App. No.
10/926,148
Granted
Jul 11, 2006
Kind
B2
Abstract

Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste and improving the overall efficiency and yield of the process.

Claims (34)

1. A process for preparing a compound of formula I:

wherein

R 1 is —CH 2 —;

R 2 is n-decyl;

R 4 is —CH 2 —;

or a salt thereof;

the process comprising:

(a) combining vancomycin or a salt thereof, with a compound of formula II:

wherein R 3 is W—OC(O)—, where W is 9-fluorenylmethyl, in the presence of base to form a reaction mixture;

(b) acidifying the reaction mixture from step (a) with an acid;

(c) contacting the reaction mixture from step (b) with a reducing agent to form a compound of formula III:

or a salt thereof;

(d) reacting the compound of formula III with an amine to provide a compound of formula IV:

or a salt thereof; and wherein steps (a), (b), (c) and (d) are conducted in the same reaction mixture without isolation of the intermediate from step (a), (b) or (c);

(e) reacting the compound of formula IV with formaldehyde and a compound of formula V:

in the presence of a base to provide a compound of formula I, or a salt thereof.

2. The process according to claim 1 , wherein the base in step (a) is a tertiary amine.

3. The process according to claim 1 , wherein the base in step (a) is diisopropylethylamine.

4. The process according to claim 1 , wherein the acid in step (b) is trifluoroacetic acid.

5. The process according to claim 1 , wherein the acid in step (b) is acetic acid.

6. The process according to claim 1 , wherein the reducing agent in step (c) is an amine/borane complex.

7. The process according to claim 1 , wherein the reducing agent in step (c) is tert-butylamine/borane.

8. The process according to claim 1 , wherein the reducing agent in step (c) is pyridine/borane.

9. The process according to claim 1 , wherein the amine in step (d) is ammonium hydroxide or a primary amine.

10. The process according to claim 1 , wherein the amine in step (d) is ammonium hydroxide, methylamine or tert-butylamine.

11. The process according to claim 1 , wherein the amine in step (d) is tert-butylamine.

12. The process according to claim 1 , wherein the base in step (e) is a tertiary amine.

13. The process according to claim 1 , wherein the base in step (e) is diisopropylethylamine.

14. The process according to claim 1 , wherein

the base in step (a) is diisopropylethylamine;

the acid in step (b) is trifluoroacetic acid;

the reducing agent in step (c) is tert-butylamine/borane;

the amine in step (d) is tert-butylamine; and

the base in step (e) is diisopropylethylamine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 047909/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033180/0199 →